Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Sorli C, Harashima SI, Tsoukas GM, et al. The Lancet Diabetes & Endocrinology 2017;5:251-260.
What it found
In adults with type 2 diabetes not yet on glucose-lowering drugs (mean HbA1c 8.05%), HbA1c fell by 1.45% (0.5 mg) and 1.55% (1.0 mg) vs 0.02% with placebo. Body weight fell by 3.73 kg and 4.53 kg on the two doses, more than with placebo. Gastrointestinal events such as nausea were the main reason for stopping treatment.
Limitations
30 weeks only and a small placebo group. Participants were early in their diabetes and on diet and exercise alone, so results may differ in people with longer-standing disease.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.